It Seems Syndax Pharmaceuticals, Inc. (SNDX) Will Go Up. Have Another Big Increase

March 14, 2018 - By Marry Poplack

The stock of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a huge mover today! The stock increased 24.86% or $2.63 during the last trading session, reaching $13.21. About 2.27M shares traded or 546.92% up from the average. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.09% since March 14, 2017 and is uptrending. It has underperformed by 9.61% the S&P500.
The move comes after 7 months positive chart setup for the $322.19 million company. It was reported on Mar, 14 by We have $13.74 PT which if reached, will make NASDAQ:SNDX worth $12.89 million more.

Analysts await Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report earnings on May, 14. They expect $-0.94 EPS, down 32.39 % or $0.23 from last year’s $-0.71 per share. After $-0.80 actual EPS reported by Syndax Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.50 % negative EPS growth.

More notable recent Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news were published by: which released: “Syndax Pharmaceuticals Undervalued On Coming Data Readouts” on February 15, 2018, also with their article: “Syndax Pharmaceuticals Inc (SNDX) Files 10-K for the Fiscal Year Ended on …” published on March 08, 2018, published: “Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor …” on March 05, 2018. More interesting news about Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) were released by: and their article: “Syndax Pharma up 21%” published on March 14, 2018 as well as‘s news article titled: “Syndax Announces Presentations at the 2018 American Association for Cancer …” with publication date: February 22, 2018.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $322.19 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: